These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1123 related articles for article (PubMed ID: 19194123)

  • 1. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
    Noda E; Maeda K; Inoue T; Fukunaga S; Nagahara H; Shibutani M; Amano R; Nakata B; Tanaka H; Muguruma K; Yamada N; Yashiro M; Ohira M; Ishikawa T; Hirakawa K
    Hepatogastroenterology; 2012; 59(113):130-3. PubMed ID: 21940361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
    Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
    Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
    Kim KH; Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Jang JS; Kim MC; Kim SJ; Kim HJ
    Biomarkers; 2011 Feb; 16(1):74-82. PubMed ID: 21133646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].
    Ishibashi K; Okada N; Ishiguro T; Kuwabara K; Ohsawa T; Yokoyama M; Kumamoto K; Haga N; Mori T; Yamada H; Miura I; Tamaru J; Itoyama S; Ishida H
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2532-5. PubMed ID: 21224630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
    Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
    Eur J Cancer; 2008 Jan; 44(1):54-60. PubMed ID: 17976974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
    J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
    Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
    Maithel SK; Gönen M; Ito H; Dematteo RP; Allen PJ; Fong Y; Blumgart LH; Jarnagin WR; D'Angelica MI
    Surgery; 2012 Feb; 151(2):162-70. PubMed ID: 21982065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
    J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
    Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
    Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
    Yoshida Y; Hasegawa J; Nezu R; Kim YK; Hirota M; Kawano K; Izumi H; Kohno K
    Cancer Sci; 2011 Mar; 102(3):578-82. PubMed ID: 21205083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.